©2022 Stanford Medicine
Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia
Trial ID: NCT04652479
The primary goal of this study is to evaluate the safety and efficacy of two different dosing regimens of an investigational drug called Avexitide in treating low blood sugar in patients with Acquired Hyperinsulinemic Hypoglycemia.
A Phase 2, Open-Label, Cross-over Study to Assess the Safety and Efficacy of Avexitide in Acquired Hyperinsulinemic Hypoglycemia
- History of bariatric or upper-gastrointestinal surgery (RYGB, VSG, gastrectomy,
esophagectomy, or Nissen fundoplication) at least 12 months prior to the start of
- History of recurrent hypoglycemia occurring after bariatric or upper-GI surgery, as
documented in the medical record.
- Body mass index (BMI) of up to 40 kg/m2
- If female, must not be breastfeeding and must have a negative urine pregnancy test
- Major surgery within 6 months before randomization.
- History of or current hyperinsulinism other than Acquired Hyperinsulinism (e.g.,
insulin autoimmune hypoglycemia).
- Use of agents that may interfere with glucose metabolism